Ensysce Biosciences, Inc.

Leisure Acquisition Corp., trading under the ticker LACQ, filed an 8-K with the SEC on November 30, 2020, in connection with its proposed business combination with Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company focused on abuse-deterrent drug technologies. LACQ is a blank-check company that completed its initial public offering in 2019 and targets the life sciences and healthcare sector. The November 2020 filing reflects a key milestone in the SPAC's de-SPAC process as it moved toward a definitive transaction with Ensysce. For full filing details, sponsor disclosures, deal timelines, and comparable SPAC transaction data, sign up for complete access at SpacDesk.